Navigation Links
Life Sciences Discovery Fund makes grants to commercialize promising technologies
Date:9/3/2014

SEATTLE, Washington, August 29, 2014 The Life Sciences Discovery Fund (LSDF) today announced nearly $750,000 in Proof of Concept grants to Washington state for-profit and non-profit organizations to promote translation of health-related technologies from the laboratory to the commercial marketplace. Also announced was nearly $56,000 in supplemental funding to an existing grant to increase the commercial potential of a drug to protect hearing in patients taking certain antibiotics. (See Backgrounder Information.)

The LSDF Board of Trustees selected the awardees following review of proposals for scientific and technical merit, commercial potential, and health and economic benefits to Washington.

The three new Proof of Concept awards will advance the development of products to improve lupus treatment and to permit at-home monitoring of lung function for individuals with asthma, chronic obstructive pulmonary disease (COPD), and other lung conditions. Funding also will support validation of novel cell separations technology for cancer immunotherapy and other medical and research applications.

"We are excited to make additional investments in the areas of autoimmune disorders and cancer and to expand our grant-making reach into lung disease management," said John DesRosier, LSDF executive director.

Board chair Carol Dahl concurred, noting that "LSDF is pleased to support the burgeoning field of mobile health technology, which represents a powerful tool for improving the overall quality and cost-effectiveness of our health-care system."

Additionally, the grant supplement of $55,990 to the University of Washington (principal investigator Edwin Rubel) will fund critical preclinical studies of a drug that appears to prevent the hearing loss associated with certain commonly used antibiotics.

LSDF is now accepting pre-proposals from Washington for-profit and non-profit organizations for the 2014-2015 Matching and Proof of Concept granting programs. The next pre-proposal submission deadline for both programs is January 7, 2015. For more details, please visit the LSDF website at http://www.lsdfa.org/, email programs@lsdfa.org, or call 206-456-9577.

Funding for the new awards comes from Washington's allocation of payments under the Master Tobacco Settlement Agreement of 1998, revenues arising from multi-state litigation with tobacco product manufacturers.


'/>"/>
Contact: Cathyryne Manner
manner@lsdfa.org
206-456-9583
Life Sciences Discovery Fund
Source:Eurekalert

Related medicine news :

1. Pall Life Sciences Signs on as Program Sponsor of the 2014 BioProcess International Awards
2. Liberty University Dedicates Its New Center for Medical and Health Sciences
3. Lauren Sciences LLC research team at Ben-Gurion University awarded grant from The ALS Association to develop V-Smart™ Therapeutic for ALS
4. Drexel College of Medicine’s Graduate School of Biomedical Sciences & Professional Studies to Host Conference to Help Graduate Students Find Careers Beyond the Bench
5. AxoGen, Inc. to Present at the Wedbush 2014 Life Sciences Management Access Conference
6. NSU’s Graduate School of Computer and Information Sciences to Host ITPalooza
7. Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate
8. Global Transcatheter Heart Valve Devices Market Outlook to 2018: Breakthrough Developments led by Abbott, Edwards LifeSciences and Medtronic
9. 5i Sciences Announces Appointment of a Senior Healthcare Consultant and Successful Financing
10. Western University of Health Sciences Elevated to “Great College to Work For” Honor Roll
11. NSU’s Graduate School of Computer and Information Sciences to Hold Special Presentations on Top 5 Technology Trends to Impact Business & IT Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, the game-changing dual ... opening of the Sober College Robert Pfeifer Memorial Learning Center at its location ... was attended by an overwhelming amount of alumni, family, colleagues and friends of ...
(Date:12/9/2016)... ... ... "I had a terrible time trying to get my grandson to use his ... had a more child-friendly design, then children would be more likely to look forward ... avoid the need to deliver medication via a nebulizer mask. The design will not ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Company LLC, announced the first national #QuackGivesBack campaign which supported local breast ... was our first franchise-wide Quack Gives Back initiative, and we’re very ...
(Date:12/8/2016)... ... 08, 2016 , ... With the increasing demand for dental implants, the National ... campaign to inform dentists and patients about the safety issues related to dental restorations. ... in the U.S. is projected to reach $6.4 billion in 2018 with more than ...
(Date:12/8/2016)... N.J. (PRWEB) , ... December 08, 2016 , ... ... delivery technologies and development solutions for drugs, biologics and consumer health products, today ... PSCI was set up in 2006 as a non-profit organization to unite pharmaceutical ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016 Allergy Diagnostics Market: Scope and ... that are used to determine the presence of ... drugs etc. in the samples by determining the ... The report on global allergy diagnostics market, analyzes ... The report consists of an executive summary that ...
(Date:12/8/2016)... de dezembro de 2016  A Mederi Therapeutics Inc . anunciou aprovação ... não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto -  ... ... Live Stretta procedure performed and broadcast during the Chinese ... Union Hospital , ...
(Date:12/8/2016)... Dec. 8, 2016  Valeant Pharmaceuticals International, Inc. ... ("Valeant") today announced positive results from a Phase ... assess the safety and efficacy of IDP-118 (halobetasol ... plaque psoriasis. Within the Phase ... to severe psoriasis, IDP-118 showed statistical significance to ...
Breaking Medicine Technology: